Alkermes plc (ALKS) Stock Price & How to Invest

Alkermes plc is an Ireland-domiciled, Nasdaq-listed biopharmaceutical company focused on the central nervous system. Its commercial base spans Vivitrol (extended-release naltrexone for alcohol and opioid dependence), Aristada (long-acting injectable for schizophrenia), and Lybalvi (an oral olanzapine/samidorphan combination for schizophrenia and bipolar I). In February 2026 it acquired Avadel Pharmaceuticals, adding Lumryz, a once-nightly sodium oxybate for narcolepsy, which broadened the portfolio into sleep medicine. The company is profitable on an adjusted basis and generates meaningful operating cash flow, which it uses to fund its pipeline rather than relying heavily on dilution.

The investment picture is a blend of steady product cash flow and pipeline optionality. The marketed drugs throw off enough revenue to keep Alkermes self-funding, but several face maturing growth curves and eventual generic or loss-of-exclusivity pressure. The upside case centers on the orexin franchise, led by alixorexton (formerly ALKS 2680), an orexin 2 receptor agonist that posted positive Phase 2 results in narcolepsy and entered a Phase 3 program in 2026, backed by FDA Breakthrough Therapy designation. Success there could reposition Alkermes as a sleep-disorder leader, while a clinical miss would leave the story leaning on aging franchises.

Clinical outcomes are binary: a Phase 3 setback for alixorexton would remove the main growth thesis and could sharply reset the valuation. Legacy franchises face patent expiries and generic competition (notably Vivitrol and the schizophrenia injectables), which can erode the cash base that funds the pipeline. The Avadel deal added integration risk and litigation exposure tied to Lumryz's competitive position against Jazz Pharmaceuticals' oxybate products. Concentration in central-nervous-system and sleep indications leaves Alkermes exposed to specific payer, pricing, and regulatory dynamics, and as an Ireland-domiciled company it also carries tax and cross-border considerations. Any of these can drive outsized share-price swings around data and regulatory catalysts.

17 analysts publish price targets on ALKS, averaging $56.00 against a $48.99 price as of August 2026, or +14.3%. The published targets run from $38.00 to $72.00, a moderate spread, and the ratings split 14 buy, 3 hold, 1 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ALKS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Alkermes plc. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Orexin pipeline optionality. Alixorexton (formerly ALKS 2680) is a once-daily orexin 2 receptor agonist that delivered positive Phase 2 data in narcolepsy types 1 and 2 and entered a Phase 3 (Brilliance) program in 2026 with FDA Breakthrough Therapy designation. The most optimistic published target, $72.00, assumes this works close to its best case.

The case against. Clinical outcomes are binary: a Phase 3 setback for alixorexton would remove the main growth thesis and could sharply reset the valuation. The most pessimistic target, $38.00, is roughly what ALKS is worth if this bites instead.

Read the full bull and bear case on ALKS, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Alkermes plc's investor relations page or your broker.

• Revenue (TTM): ~$1.5B
• Q1 2026 revenue: ~$393M (+28% YoY)
• Q1 2026 adj. EBITDA: ~$80M
• Q1 2026 GAAP net loss: ~$(67)M
• Market cap: ~$8.5B
• 2026 top-product guidance: Vivitrol ~$460-480M, Lybalvi ~$380-400M

First-quarter 2026 revenue of roughly $393 million rose about 28% year over year, helped by product growth and the newly consolidated Lumryz, though the quarter showed a GAAP net loss partly reflecting Avadel deal costs. Adjusted EBITDA of around $80 million underscores the underlying profitability of the marketed portfolio. At an approximately $8.5 billion market cap on roughly $1.5 billion of trailing revenue, the market is pricing in meaningful pipeline value beyond the current product base.

If you want ALKS exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to ALKS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ALKS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (FBT, IJT, SLYG), which spreads the position across many companies. Or build it into a focused thematic portfolio, so ALKS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ALKS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

ALKS pairs a self-funding specialty-pharma base with a high-stakes orexin pipeline, so the investment case hinges on whether narcolepsy data can offset maturing legacy franchises.

Whether ALKS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ALKS a buy or a sell?, and where the stock could go from here in the ALKS stock forecast.

For income investors, whether ALKS pays a dividend and how the payout looks is covered in does ALKS pay a dividend? And to weigh ALKS against a peer, read the full side-by-side comparisons: ALKS vs JAZZ and ALKS vs JNJ.